Compare the Treatment Effects of Various Therapies for Breast Cancer Based on Data Analysis

Yimeng Zhao

doi:10.62051/8j5m3w69

Authors

Yimeng Zhao

DOI:

https://doi.org/10.62051/8j5m3w69

Keywords:

Breast cancer; modified radical resection; Immunotherapy; Targeted drug therapy.

Abstract

Breast cancer is one of the life-threatening tumors around the world. While some researchers have discovered a strong correlation between human health issues in contemporary society and the medication of breast cancer, a comparison of the impacts of different breast cancer treatments is still lacking in the literature. Thus, for the purpose of compare the therapeutic outcomes of targeted medication therapy, immunotherapy, and surgical treatment, this research gathers clinical treatment data and does SPSS data analysis. Research has demonstrated the efficacy of surgical intervention, immunotherapy, and targeted medication therapy in the managing the remedy of breast cancer. The specific targets of each therapeutic modality vary. Individuals diagnosed with advanced breast cancer may select several treatment options based on their unique circumstances.

Downloads

Download data is not yet available.

References

[1] Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. (2020)

[2] L. Pan, J. F. Wu, S. N. Guo, et, Research progress on the regulation of breast cancer stem cells and targeted therapy, Chinese Journal of Cell Biology,2024,46(03):568-575

[3] Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID: 34905391; PMCID: PMC8822551.

[4] Q. Zhang, B. Q. Xiu, J. Wu, Important clinical research results and latest progress of breast cancer in China in 2023, China Oncology,2024,34(02):135-142.DOI:10.19401/j.cnki.1007-3639.2024.02.001.

[5] Z. Q. Liu, J. G. Dai. Research progress of modified radical mastectomy for breast cancer [J]. Modern medicine and health,2024,40(08):1349-1352+1357.

[6] Y. Li, Q. Liu. Advances in immunotherapy for breast cancer [J]. Journal of Clinical Surgery,2019,27(03):187-190.

[7] J. Q. Zhang, H. Y. Jia. Advances in the study of PD-1/PD-L1 inhibitors in breast cancer [J]. Chinese Journal of Basic and Clinical Surgery,2021,28(11):1530-1535.

[8] Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. PMID: 30475950.

[9] Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. PMID: 30242306; PMCID: PMC6439773.

[10] Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2804-2811. doi: 10.1158/1078-0432.CCR-17-3452. Epub 2018 Mar 20. PMID: 29559561.

[11] Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23. PMID: 29063313; PMCID: PMC5807460.

[12] C. H. Wang, P. He. Efficacy of Herceptin in the Treatment of Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer [J]. Drug evaluation,2017,14(06):59-61.